Dividend Calendar: Week of April 13, 2026

The week of April 13, 2026 presents dividend investors with an attractive lineup of income-generating opportunities across multiple sectors. This week’s ex-dividend calendar features 15 established companies offering yields ranging from 2.11% to 6.39%, with particular strength in telecommunications, pharmaceuticals, and energy sectors.

High-yield opportunities dominate the weekly roster, with six companies offering yields above 3.5%. Telecommunications giants Pfizer and Verizon lead the pack with yields exceeding 6%, while energy stalwart Chevron and pharmaceutical leader Bristol-Myers Squibb round out the premium yield category.

Ex-Dividend Calendar

Notable High-Yield Opportunities

Pfizer leads this week’s dividend calendar with a compelling 6.39% yield on its $1.72 quarterly distribution. The pharmaceutical giant continues to reward shareholders despite ongoing patent cliff challenges. Verizon follows closely with a 6.01% yield, offering $2.77 per share as the telecom sector maintains its reputation for consistent income generation.

Bristol-Myers Squibb presents a 4.26% yield with its $2.50 dividend, while AT&T rounds out the telecommunications representation with a 4.19% yield. Energy sector representation comes from Chevron, delivering $6.91 per share for a 3.67% yield, and Exxon Mobil contributing $4.04 per share at 2.65%.

Sector Diversification

This week’s calendar showcases strong sector diversification, with healthcare leading the count at five companies (PFE, BMY, ABBV, MRK, JNJ, GILD), followed by consumer staples (PEP, PG, KO), energy (CVX, XOM), telecommunications (VZ, T), and financial services (USB, WFC). This broad representation provides income investors multiple avenues for portfolio diversification.

The pharmaceutical and healthcare sector dominance reflects the industry’s mature cash flows and commitment to shareholder returns, while the presence of consumer staples giants like PepsiCo, Procter & Gamble, and Coca-Cola underscores the defensive nature of dividend-focused portfolios.

This information is for educational purposes only and should not be considered investment advice. Dividend payments and yields are subject to change. Past performance does not guarantee future results. Consult with a qualified financial advisor before making investment decisions.

How to Use This Calendar

The ex-dividend date is the single most important column in the table above. To receive a dividend, an investor must own shares before the market opens on the ex-date. A common misconception is that buying on the ex-date itself qualifies you for the payment — it does not. U.S. equities trade on a T+1 settlement cycle as of 2024, which means a trade executed on Monday, April 13 settles on Tuesday, April 14. Since the ex-date is defined by settlement-date ownership, any purchase on the ex-date itself will not appear on the company’s books in time to capture the dividend.

The payment dates listed as TBD will be confirmed in the 1-2 weeks leading up to each company’s earnings and dividend announcement cycle. Historically, large-cap dividend payers like Pfizer, Verizon, and Chevron declare on a quarterly cadence (typically late January, late April, late July, late October), and the cash payment follows roughly 4-6 weeks after the ex-date. Investors who already hold these positions at the start of the week will receive the indicated cash amounts automatically — no action is required.

Reading Yield Numbers Carefully

The yields shown in the table are trailing twelve-month yields calculated against the current share price, not the company’s forward guidance. This matters more than it might appear: a 6.39% indicated yield on PFE (Pfizer) reflects the share price decline from its 2024 peak rather than an increase in absolute dividend dollars. If PFE were still trading near its 2024 high of $36, the same $1.72 quarterly payout would imply a yield closer to 4.7%. Investors evaluating Pfizer as a yield play should confirm whether the dividend is covered by sustainable free cash flow — for a major pharmaceutical company with a mature drug pipeline, the answer is generally yes, but it is worth checking each company’s most recent 10-K filing rather than relying on the headline yield alone.

By contrast, lower yields in the 2-3% range (PG at 2.91%, KO at 2.66%, XOM at 2.65%) signal companies with more stable share prices where the dividend itself represents a smaller, but more predictable, slice of total return. For Japanese investors purchasing U.S. equities through most online brokers, these lower-yield names often behave more like a bond proxy within an equity allocation — useful for portfolio diversification but rarely worth buying purely for income.

Why This Calendar Matters for Japanese Investors

U.S. dividend payments are subject to a statutory 30% withholding tax for non-resident investors, but the U.S.-Japan tax treaty reduces this to 15% for most account types, and to 10% for portfolio investors who properly document their status through a W-8BEN form filed with their broker. For Japanese retail investors holding U.S. equities through a domestic broker (SBI Securities, Monex, Rakuten Securities, etc.), the W-8BEN is typically submitted automatically during account setup — but it is worth confirming with the broker that the form is on file, since the moment a dividend payment is missed, the higher rate cannot be retroactively reclaimed for that quarter.

Japanese NISA accounts have an important wrinkle here. The Tsumitate枠 (accumulation account) is designed exclusively for diversified mutual funds and does not cover direct U.S. stock holdings. The Growth Investment枠 (formerly the general NISA account) does cover direct U.S. equities, with the annual contribution limit set at 3.6 million yen per calendar year as of 2026, and a lifetime tax-free ceiling on unrealized gains. Dividends received inside the NISA Growth Investment枠 are tax-free at the Japanese level. Capital gains from selling a U.S. stock held inside NISA are also tax-free, even if the eventual sale price reflects accumulated dividends that were reinvested.

For Japanese investors building a long-term portfolio, the practical workflow is: identify these U.S. dividend payers using KabuWire’s weekly calendar, then purchase through a NISA-eligible account where possible. The combination of the reduced 10% U.S. withholding rate plus NISA’s zero-tax treatment in Japan can compound meaningfully over a 5-10 year holding period.

Currency Risk and Timing

Dividends are paid in U.S. dollars to Japanese holders, then converted to yen at the prevailing exchange rate on the payment date — not on the announcement date or the ex-date. For the week of April 13, 2026, the USD/JPY exchange rate was fluctuating in the 145-148 range as markets digested delayed U.S. tariff announcements and Bank of Japan policy normalization. Investors who received $1.72 per PFE share during this week effectively received between ¥249 and ¥255 per share before Japanese tax treatment — a wider band than the headline dividend figure suggests.

This currency timing means that for Japanese investors, the “best” week to receive a USD dividend is when the yen is weakest relative to the dollar, even though the company’s payment schedule has nothing to do with FX markets. Over a 12-quarter holding period, FX swings of 5-10% can erase or double the effective yield in yen terms, which is one reason most Japanese advisors recommend treating U.S. dividend payers as a hybrid equity-currency position rather than a pure income play.

Looking Ahead: Next Ex-Dividend Catalysts

Of the 15 names in this calendar, six companies (PFE, VZ, BMY, T, USB, CVX) are scheduled to declare their next quarterly dividend in late April to early May 2026, with corresponding ex-dates in mid-to-late May. Investors building positions around the current ex-date should already be researching whether the next declared dividend is expected to hold flat, increase, or signal a warning. For pharmaceutical names (PFE, BMY, MRK), earnings in late April will be the most important catalyst — a dividend cut alongside weak earnings is the most common failure mode for high-yield equity names.

The remaining names in the calendar (PEP, ABBV, PG, KO, XOM, MRK, CNC, AVGO, O, NEE) are scheduled to follow their own quarterly cadence, with ex-dates spread across Q2 2026 in roughly 2-4 week intervals. KabuWire will publish the next iteration of this weekly calendar as the ex-dates approach, with the same yield and sector breakdown structure used here.